Daily Ocular Symptom Severity Score (DOSSS)
DOSSS was calculated as the mean symptom score across all ocular symptom severity components daily (including itchy, watery, ore red eyes), each scored by patients according to a 4-point scale (0, none; 1, mild; 2, moderate; 3, severe). Four studies with 949 randomized patients provided enough data to allow for a quantitative evidence synthesis based on the DOSSS. Overall, omalizumab statistically significantly reduced the DOSSS score by a summary standardized mean difference of -0.30 points (95% CI, -0.50, -0.09; p=0.004; I2 = 86.2%) (Figure 3).